Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes

BACKGROUND: Paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS) have a very poor prognosis: more than half of the patients become bedridden and median survival is less than 12 months. Several lines of evidence suggest a pathogenic T cell-mediated immune response. Therefore, we con...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastiaansen, Anna E M, de Jongste, Adriaan H C, de Bruijn, Marienke A A M, Crijnen, Yvette S, Schreurs, Marco W J, Verbeek, Marcel M, Dumoulin, Daphne W, Taal, Walter, Titulaer, Maarten J, Sillevis Smitt, Peter A E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528262/
https://www.ncbi.nlm.nih.gov/pubmed/34693289
http://dx.doi.org/10.1093/noajnl/vdab145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528262/
https://www.ncbi.nlm.nih.gov/pubmed/34693289
http://dx.doi.org/10.1093/noajnl/vdab145

Ejemplares similares